Evidence map›Paper›PMID 40875209›Full record

ArticleClinical transplantation2025

Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis.

Anja Gaeckler, Imad Al-Dakkak, Nuria Saval, Hans Herman Dieperink, Margriet Eygenraam, Larry A Greenbaum, Nicole Isbel, Johan Vande Walle

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01522183 (An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01522183 recruitingnot on this map

An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome (aHUS Registry)

Typeobservational_patient_registrySponsorAlexion Pharmaceuticals, Inc.Ran2013 to 2031Enrolled3,000ConditionsAtypical Hemolytic-Uremic Syndrome
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anja GaecklerDepartment of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Imad Al-DakkakGlobal Medical Affairs, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
Nuria SavalGlobal Medical Affairs, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
Hans Herman DieperinkDepartment of Nephrology, Odense University Hospital, Odense, Denmark.
Margriet EygenraamaHUS Canada, Brampton, Ontario, Canada.
Larry A GreenbaumDivision of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Nicole IsbelDepartment of Kidney and Transplant Services, The University of Queensland and Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Johan Vande WalleDepartment of Pediatrics and Medical Genetics, Ghent University Hospital, Ghent, Belgium.

Funding

Alexion, AstraZeneca Rare Disease, Boston, MA, USA
6 · The paper itself

Abstract

introductionAtypical hemolytic uremic syndrome (aHUS) is a disease of complement dysregulation that may lead to kidney failure. Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of aHUS. This study assessed the real-world effectiveness and safety of switching to ravulizumab from eculizumab in kidney transplant recipients with aHUS.

methodsThe Global aHUS Registry is a multicenter study enrolling patients with aHUS since 2012. Effectiveness and safety outcomes were assessed in kidney transplant recipients with aHUS who switched to ravulizumab from eculizumab up to September 2, 2024.

resultsOverall, 38 patients received a kidney transplant before ravulizumab initiation; 27 patients with ≥3 months of ravulizumab treatment were included in the patient characteristics and effectiveness analyses. Median (range) time on eculizumab and ravulizumab treatment was 66.1 (3.7, 158.3) and 24.1 (4.2, 49.3) months, respectively (n = 27); time from last kidney transplantation to ravulizumab initiation was 65.9 (3.7, 184.0) months. Following ravulizumab initiation, laboratory parameters remained stable, and no kidney transplant rejections/graft failures were reported. In the safety analysis (n = 38), 23 adverse events were reported in 19 patients (50.0%) at or after ravulizumab initiation, and none were considered treatment-related. No new events of thrombotic microangiopathy or kidney impairment and no meningococcal infections or deaths were reported.

conclusionThis analysis from the Global aHUS Registry provides real-world evidence to demonstrate that the transition to ravulizumab from eculizumab in kidney transplant recipients with aHUS is successful, with stable graft function with no treatment-related safety concerns.

trial registrationClinicalTrials.gov identifier: NCT01522183.

Indexed as

Antibodies, Monoclonal, HumanizedAtypical Hemolytic Uremic SyndromeComplement Inactivating AgentsDrug SubstitutionGraft RejectionKidney Failure, ChronicKidney TransplantationAdultAgedFemaleFollow-Up StudiesGlomerular Filtration RateGraft SurvivalHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedComplement Inactivating Agentseculizumabravulizumabatypical hemolytic uremic syndromecomplementglobal aHUS registrykidney transplantationravulizumabreal‐world datathrombotic microangiopathy

Identifiers

PMID40875209
PMCPMC12393192

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.